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Abstract
Background: Non-Invasive Prenatal Testing (NIPT) is a technology which provides information about fetal genetic
characteristics (including sex) very early in pregnancy by examining fetal DNA obtained from a sample of maternal
blood. NIPT is a morally complex technology that has advanced quickly to market with a strong push from industry
developers, leaving many areas of uncertainty still to be resolved, and creating a strong need for health policy that
reflects women’s social and ethical values. We approach the need for ethical policy-making by studying the use of
NIPT and emerging policy in the province of Ontario, Canada.
Methods: Using an adapted version of constructivist grounded theory, we conducted interviews with 38 women
who have had personal experiences with NIPT. We used an iterative process of data collection and analysis and a
staged coding strategy to conduct a descriptive analysis of ethics issues identified implicitly and explicitly by
women who have been affected by this technology.
Results: The findings of this paper focus on current ethical issues for women seeking NIPT, including place in the
prenatal pathway, health care provider counselling about the test, industry influence on the diffusion of NIPT,
consequences of availability of test results. Other issues gain relevance in the context of future policy decisions
regarding NIPT, including funding of NIPT and principles that may govern the expansion of the scope of NIPT.
These findings are not an exhaustive list of all the potential ethical issues related to NIPT, but rather a
representation of the issues which concern women who have personal experience with this test.
Conclusions: Women who have had personal experience with NIPT have concerns and priorities which
sometimes contrast dramatically with the theoretical ethics literature. These findings suggest the importance
of engaging patients in ethical deliberation about morally complex technologies, and point to the need for
more deliberative patient engagement work in this area.
Keywords: Non-invasive prenatal testing, Prenatal screening, Qualitative research, Ethics, Health policy, Patient
engagement
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Background
This study examines women’s perspectives on the fastgrowing, ethically-complex technology: non-invasive
prenatal testing (NIPT). NIPT is used to screen for genetic characteristics including chromosomal aneuploidy
(e.g. Trisomy 21 or Down syndrome), sex chromosome
anomalies, and fetal sex, from fetal DNA obtained in a
sample of maternal blood [1–3]. NIPT can be used as
early as 9 or 10 weeks gestation [3–6]. It is more accurate than the tests involved in traditional forms of prenatal screening [7–10]. However, it is still a screening
rather than a diagnostic test, meaning that the results
should be understood to indicate risk rather than make
a diagnosis. The “non-invasive” nomenclature designates
that NIPT is not associated with the risk of miscarriage
that exists with diagnostic tests such as amniocentesis or
chronic villus sampling (CVS) [3–6]. These benefits
aside, NIPT is an example of what Hoffman has called a
“morally challenging technology” [11] because it poses
moral issues which are broader than the specific technology, such as sex selection and eugenics, and because
it has implications for larger groups than those who
interact directly with the technology, such as persons
with disabilities. NIPT poses some new moral issues,
and it exacerbates or reinforces others which have long
been identified as related to other forms of prenatal testing. New ethical issues posed by NIPT include the worry
that it may facilitate sex selective termination by providing accurate information about fetal sex within the first
trimester [5, 12]; the availability of potentially anxietyprovoking information about genetic traits of unknown
clinical significance [13, 14]; and the scientific possibility
of using NIPT for an expanded slate of conditions that
have decreasing impact on functioning, or which are
late-onset conditions, or conditions with variable penetrance [15]. The development and diffusion of NIPT has
been driven by industry which has resulted in the test
being market before validated, unbiased evidence of
efficacy was available, and which may restrict future development and affordability of the test [14–16]. In countries where NIPT is not publicly funded, there may be
equity issues surrounding who can access NIPT and
what other opportunities that access creates (i.e. earlier
access to invasive testing and termination) [5, 13, 17].
Exacerbated or continuing ethical issues include the
concern that increasing levels of routinization and diminished facilitators for women to make informed
choices may result in increased discrimination against
people living with disabilities [18–21].
NIPT has diffused quickly into mainstream prenatal
practice in many high resource countries, largely driven
by industry imperatives [22]. In Ontario, Canada, where
this study takes place, NIPT has been commercially
available since 2011, and publicly funded for women at

Page 2 of 13

high risk of aneuploidy since 2014 [23, 24]. Ontario offers publicly funded prenatal screening and diagnosis as
part of a provincial health insurance plan that funds hospital and physician services. All pregnant women are offered prenatal screening through a provincial program
established in the mid 1990s [25]. In 2014, NIPT was
publicly funded on a case-by-case basis as a form of
second-tier screening, most commonly accessed when
initial screening yields results indicating the pregnancy
to be at higher risk. Depending on the initial screening
modality chosen, the initial screening results may not be
available until the middle of the second trimester, so
under the current policy, many Ontario women consider
the offer of publicly funded NIPT quite late in pregnancy [24]. Other Ontario women may access publicly
funded NIPT if they are over the age of 40 at the expected date of delivery, or have previously had an affected pregnancy. NIPT is available in Ontario as a
private pay technology at any time.
As a result of the quick diffusion of NIPT, policy
makers in many jurisdictions are tasked with making a
number of decisions regarding how best to implement
NIPT in the prenatal care pathway, which health professionals should be involved in counselling, and how to
handle the growing number of clinical applications for
NIPT [26]. While some jurisdictions have started to publicly fund NIPT in specific circumstances [24, 27–29],
many other jurisdictions are in the process of assessing
this technology prior to policy decision-making, through
Health Technology Assessment, or other policy-making
processes.
The importance of including patient and user perspectives has been well studied within the policy context of
health technology assessment (HTA) [30–32]. Enthusiasm for patient engagement is not limited to HTA; other
health policy venues are increasing their capacity and refining their approach to including patient and public
perspectives in policy decisions e.g [33, 34]. Patient perspectives provide an important source of information for
ethical policy-making, particularly by illuminating issues
which may not be considered or may be de-prioritized
when decision-makers focus on clinical efficacy and cost
[31, 35–37]. The growing number of women who have
had personal experience with NIPT can contribute personal values, experiences, and beliefs to inform future
policy decision-making about this technology. The perspectives of users and other stakeholders can provide
unique understandings of policy implications. Critical reflection on these perspectives may provide insight into
the ethical implementation of NIPT, contributing to policy that is comprehensive, morally justifiable, and able to
gain public support [30, 32, 35]. Incorporating patient
perspectives also promotes policy that is responsive to
the needs and wishes of the people who will be effected
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by the policy decisions, and in so doing increases the
likelihood that the policy will be accepted and
adopted [30, 35, 38].
Since the concept of NIPT was first introduced, ethical
analysis of this technology has proliferated, primarily
representing theoretical perspectives, e.g. [15, 39–43]. As
the uptake of NIPT has grown, empirical research on
the views, opinions, and knowledge of the public, pregnant women, and clinicians has also occurred [24, 44–50].
Despite these two burgeoning research streams, there has
been little cross-over, with only a few of the empirical examinations of stakeholder experiences explicitly addressing the ethical implications of their findings [26, 51–54].
Without a strong connection between theory and empirical evidence of stakeholder opinions towards NIPT, we
lack a rigorous understanding of what ethical issues matter to the users of this technology. Towards the goal of
contributing to ethical policy that reflects patient preferences, we examined women’s perceptions of ethics issues
related to NIPT by asking “How do women understand
the ethics implications of the implementation of NIPT in
Ontario, Canada?” These findings may inform policy deliberation in a wide variety of ways, and their usefulness
will vary according to the specific policy question under
consideration and the mode of policy decision-making.
These findings may contribute to construction of
patient-relevant outcomes in an economic analysis
[55], determination of optimal placement of NIPT in
the clinical pathway, design of patient education materials, or inform ethical and social analysis in a
health technology assessment of NIPT.

Methods
The methods for this adapted constructivist grounded
theory study have been described in detail elsewhere
[24]. Briefly, we conducted thematic analysis on semistructured interview data collected within the context of
a constructivist grounded theory study to describe
women’s perceptions of ethical issues pertaining to
NIPT. We conducted semi-structured interviews with 38
women purposively sampled because they had a variety
of personal experiences with NIPT (Table 1). All women
lived in Ontario, but some had accessed NIPT in other
jurisdictions. To ensure our sample included women
with diverse experiences, participants were recruited
through a high risk prenatal diagnosis clinic using a
consent-to-contact form presented by their clinician, ads
on online classified sites (e.g. Kijiji), online pregnancy
and parenting sites, and via snowball sampling. We initially recruited women living in Ontario who had any
personal experience with NIPT. As the project progressed, we used the iteration between data collection
and analysis to theoretically sample particular groups of
interest (e.g. women who declined NIPT, women who
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Table 1 Testing Pathway of Participants (N = 38)
Number
Number of Women

38

Number of Offers of NIPTa

42

Percent

Accepted NIPT at Least Once
Yes

30

79%

No

8

21%

Funding for NIPT
Eligible for public funding, accepted NIPT

19

45%

Eligible for public funding, declined NIPT

7

17%

Ineligible for public funding, accepted NIPT

13

31%

Ineligible for public funding, declined NIPT

3

7%

6

14%

Point in Pregnancy NIPT Considered
Preconception
First Trimester

12

29%

Second Trimester

24

57%

2

5%

Reason for Considering NIPT
Advanced Maternal Age (≥ 40 years)
Previous Affected Pregnancy

3

7%

Recurrent Unexplained Miscarriages

1

2%

Screened positive from FTS

4

10%

Screened positive from IPS

14

33%

Soft markers on 2nd Trimester Anatomy Scan

8

19%

No elevated risk factors, desire for general
information

10

24%

FTS First Trimester Screening, IPS Integrated Prenatal Screening
a
35 women discussed one offer of NIPT. Two women discussed two separate
instances in which they were offered NIPT, one woman discussed three
separate offers of NIPT

were offered NIPT in the preconception period). We recruited these groups by tailoring our strategy in several
ways, e.g. asking clinicians at the clinic to give the
consent-to-contact form to certain types of women, rather than any woman offered NIPT, and by screening interested women who contacted us from our online
advertisements.
We explained our study to participants as aiming to
gather women’s values, experiences, and opinions on
NIPT in the hopes of potentially informing future policy
about this new health technology. After eliciting personal experiences and values about this technology
(findings described in [24]), we entered an in-depth discussion of ethical implications by asking women to describe their thoughts on the advantages, disadvantages,
concerns and benefits of this new technology. As interviewers, we adapted our conversational style to match
the level of engagement each participant had with these
ethics ideas. Some women needed little prompting, and
spoke at length about their concerns and excitement
about NIPT, in response to broad questions designed to
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allow unanticipated ethical issues to emerge. Others required a more structured approach, and we used interview probes to explore thoughts related to regulation
and funding, expansion to other conditions, implications
for reproductive decision-making and social impacts.
The interview guide is provided as a supplementary file
to this manuscript (see Additional file 1) While the
women in this study were familiar with NIPT by virtue
of their own involvement with it, we did not provide any
education about the technology and asked women to respond to our questions based on their existing knowledge, opinions and beliefs.
Two researchers (MV, AC) conducted a thematic analysis of ethics implications identified by women. We analyzed our data using the staged coding technique of
grounded theory, looking specifically for mentions of issues which we judged to have ethical implications. Participants did not need to explicitly identify an issue as
ethical for it to be included in our coding; we also identified implicit ethical issues. For example, participants
often discussed the price of NIPT as a barrier to accessing the test. While discussions centered on the financial
implications, we would code this type of talk as ethically
relevant because it is related to issues such as equity of
access. Our identification of ethics issues was informed
by a familiarity with the broad literature on ethical implications of prenatal screening. We did not use any particular ethics theory as a theoretical lens for this
descriptive analysis, but as reflexive researchers we
recognize that our existing ethical commitment to theories such as relational autonomy and feminist ethics [56,
57] colour the way we identify and describe ethical
issues.
We began by working independently to conduct lineby-line coding with the intent of identifying ethical issues. We met periodically throughout this process to
discuss and compare the issues we were identifying.
After line-by-line coding was completed, we consulted
with the rest of the research team to identify a direct for
focused coding. Further rounds of focused coding permitted the condensation of these themes into categories.
Discussion with the broader team helped form the findings presented in this manuscript. NVivo® 10 software
was used for data management.
This study received research ethics approval from the
Hamilton Integrated Research Ethics Board.

Results
Thirty-eight women participated. Table 1 describes the
range of experiences these women had with NIPT and
Table 2 describes their demographics. In general, our
participants were older, more educated and more likely
to receive care from a family physician than the average
Canadian pregnant woman [58, 59]. Our sample reflects
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Table 2 Demographic characteristics of study participants (N = 38)
Number

Percent

Singleton

37

97%

Twin

1

3%

Family physician

17

45%

Obstetrician

13

34%

Midwife

2

5%

Fertility specialist

2

5%

Family physician + obstetrician

3

8%

Family physician + midwife

1

3%

25-29 years

2

5%

30-34

14

37%

34-39

16

42%

40+

6

16%

Zero

9

24%

One

19

50%

Pregnancy

Primary prenatal care provider

Age at delivery (mean = 35.4 yrs)

Number of existing children

Two

9

24%

Three or more

1

3%

Urban

26

68%

Suburban/town

9

24%

Rural

3

8%

13

34%

Christian

7

18%

Jewish

5

13%

Location of Residence

Religiosity
Considers self “religious”

Christian + Jewish
Does not consider self “religious”

1

3%

25

66%

1

3%

Highest level of education
High school degree
College degree

7

18%

University undergraduate degree

13

34%

University graduate or professional degree

17

45%

a diverse array of experiences with NIPT, including
women who accepted and declined the test, and those
who were offered NIPT at all stages of pregnancy and
for a variety of indications.
We identified many ethical issues related to the research participants’ experiences with the process of
NIPT. Many of these issues (e.g. routinization, impact
on people with disabilities) have been well described in
existing literature about other prenatal tests. We concentrate here on describing the identified ethics issues
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unique to, or exacerbated by, NIPT and have organized
these results based on their primary level of impact.
Those which pertain to women currently seeking the
test are presented first, followed by issues which gain
relevance in the context of future policy decisions. Four
categories of ethical issues are identified: Inconsistent
Implementation of a Quickly Evolving Industry-Driven
Technology, Early Availability of Results, Financial Considerations, and Potential for Expansion of NIPT.
We do not claim that the issues identified by the
women in our study represent an exhaustive list of possible ethical implications of NIPT. Rather, these findings
represent the understandings, concerns, and priorities of
women who have had personal experience with this
technology in Ontario, Canada.
Quotes from participants are contextualized with information about whether that woman accepted (A) or
declined (D) NIPT, the trimester of pregnancy in which
NIPT was offered (1, 2 or P for preconception). The “$”
notation indicates the woman was eligible for publicly
funded NIPT. Accordingly, D1$ indicates a woman who
declined a first-trimester offer of publicly funded NIPT.
Three women were offered NIPT more than once, and
each offer is noted individually. For example, “A2 A1
A1” describes a woman who paid privately for NIPT in
multiple pregnancies.

Inconsistent implementation of a quickly evolving
industry-driven technology

Participating women identified a number of concerns
about the way that NIPT has been implemented in Ontario, where industry imperatives have meant wide dissemination of the technology in absence of systematic
regulation or organization at a policy level. As a result of
this organic dissemination, women expressed dissatisfaction with several aspects of NIPT implementation including inconsistency in the information and counselling
received from different health care providers and the restriction of the offer of NIPT to women who are at identifiably high risk. We implicitly identified several other
issues related to industry influence on dissemination.
Twenty women in our study discussed an unsatisfactory experience with the way health care providers discussed NIPT. Women who discussed it with their
primary care provider typically remarked that they did
not perceive this person to be well-informed about the
test: “I talked to my doctor about it and I’m not sure she
knew too much about what the risks are. It didn’t ease
my mind very much” (A2$). In contrast, those who had
the opportunity to discuss NIPT with a specialist provider were generally pleased with the interaction: “The
genetic counsellor was amazing so whatever their background is, I don’t know but they’re doing a good job. Not
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to discredit my family physician but I didn’t feel like they
were very prepared or good at explaining it to me” (A2$).
We identified an inconsistency between the way that
NIPT is currently offered in Ontario and women’s preferences for who should offer NIPT and when that offer
should occur. Few of our participants were offered NIPT
by a primary care provider in absence of a particular risk
factor, but many women favour this approach: “It needs
to start with the GPs. I mean, that’s the first person typically that you’re going to see when you find out you’re
pregnant and I think it needs to be a part of the conversation right from the beginning.” (A2$) Our participants
were overwhelmingly in favour of all women being offered NIPT as part of the initial conversation on prenatal
screening, regardless of whether or not NIPT is publicly
funded. This view remained consistent even when opinions were probed in response to the cost burden of
NIPT for women who did not qualify for public funding,
the time pressures on primary health care providers, the
potential for iatrogenic anxiety, and the for-profit nature
of this test: “When you go in for that first appointment
and the doctor lays out what all the testing is, I don’t
think it would be such a big, scary deal if it was just
made part of that. An option within routine care. I don’t
know why somebody would withhold the possibility of
having that test” (AP).
Across our dataset, we identified several issues of inconsistent implementation related to the private development and diffusion of NIPT through industry, without
governmental regulation. These ethics issues were
mostly identified implicitly, and include the competition
between brands of NIPT, a concern that physicians or
hospitals were incentivized to encourage uptake of NIPT,
and strong marketing messages about NIPT. Regarding
competition between brands, we heard very little about
making a choice between the available NIPT brands.
Typically, those who discussed multiple brands focused
on logistical reasons for their choice: “I had the Panorama instead of the Harmony just because that’s what’s
offered at the lab.” (A2$). Most women were not concerned about the relationship between this private-pay
test and their health care provider, with only three
women raising the issue. For these women, the perception that a physician or hospital may benefit from the
uptake of a prenatal screening test may disrupt the trust
in the physician-patient relationship: “I would say he
was pushing during that appointment. … He had pamphlets in his office that he was distributing. I don’t know
if a rep had been into the office and if they were getting
any kind of a cut.” (D2$). We saw evidence that strong
marketing messages about NIPT were internalized by
many participants, leading to inaccurate understandings
of the test. This phenomenon was most notable around
women’s understanding of accuracy rates. Most women
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conflated the detection rate for Trisomy 21 to be the detection rate for all conditions. Trisomy 13 and 18 have a
lower detection rate and positive predictive value, or the
probability that a woman with an affected pregnancy
would receive a positive result, especially in normal-risk
women: “It’s so precise. Like 99% accurate. The accuracy
rate is amazing. I think that’s what’s great about it.”
(A2$) Very few participants were skeptical about detection and accuracy rates, with only a small number of
highly educated women mentioning this issue: “it’s a
newer test, so what is the error rate?” (D2$).

outraged if it existed and I wasn’t given the opportunity”
(A2 A1 A1). This sentiment was particularly strong
amongst women who understood NIPT to be a superior
substitute for existing prenatal screening pathways, and
expressed their willingness to substitute NIPT for
current screening methods: “If this screening tool is
available, and if it’s that much better than what’s currently offered, I don’t know why they wouldn’t substitute
it. Just like if a better medical practice comes along, then
we adopt that practice” (A1$).

Early availability of results

Financial considerations

NIPT can be used as early as 9 or 10 weeks gestation,
depending on the brand selected, with results available
approximately 10 days later. This is significantly earlier
than results from other screening tests which may not
be available until 14-20 weeks, depending on the testing
modality. The early availability of NIPT results was mentioned often, and we identified two related ethics issues.
First, because results are available within the time frame
that pregnancy termination is readily available, some
women feared that NIPT would be used for sex selection. “If it can tell you gender that early, well then you
have a lot of options in terms of terminating if it’s not the
gender you wanted. I’d be very wary of that, if you are
using it for that purpose” (A2$). While the topic of sex
selection dominated this conversation, many participants
mentioned a fear that the conditions detected by NIPT
would expand, and it may be used to terminate for reasons they judged distasteful. “You get into a sticky situation because then you have people who will abort for
what some of us consider irresponsible reasons” (DP).
The applications of NIPT that women judged distasteful
varied by participant and will be discussed further at the
end of this section.
While the possibility of early termination was seen as
negative in some circumstances, it was seen as positive
in other situations, because an early termination would
obviate some of the physical and emotional difficulties
encountered with later termination: “You feel the baby
moving and the emotional impact of it—it’s already a
terrible decision to make but the longer you stay pregnant the worse it is.” (D1$).
All participants supported earlier access to NIPT, and
access to NIPT for all women. This opinion was consistent even among those who declined NIPT, those who
stated they would never consider terminating their own
pregnancy, and even after the interviewer probed about
the possibility of using NIPT for sex selection. This sentiment was so strong that we could identify an argument
that patient-centered policy in this area should enable
rather than restrict access to a technology which would
facilitate earlier decisions about termination. “I would be

Some research participants were concerned with the
cost implications of NIPT to the publicly-funded healthcare system. “It’s always hard to know how to distribute
the resources” (D2$) Many women mused about the cost
differences of NIPT versus the existing prenatal screening pathway, on the budget impact of publicly funding
NIPT, and on the cost of the additional counselling and
health care providers that would be required: “The other
screening that I did involved two blood tests and an
ultrasound so I can’t imagine that’s cheap either” (A2$).
Within women’s discussions of whether NIPT should
be publicly funded and if so, for whom, we identified
several ethical issues related to the economic assessment
of this technology. For example, what outcomes should
be used in an assessment of cost-effectiveness? Many
women suggested that the government might consider
potential savings in long-term health care costs when affected pregnancies are terminated: “What they’re paying
out in testing they might be saving down the line in cost
of care for highly disabled children, their hospital care,
their intensive care, whether they make it beyond a certain number of weeks, months, whatever” (D1$). Others
cast this issue as a need to plan for the support of people
with disabilities, rather than calculating how much
money would be saved by preventing those births: “They
[parents] will take care of their kids [with disabilities]
but they do need the support from society and then we
can actually plan long term resources” (A2$).
A few women suggested the need to consider nonmonetary outcomes such as reducing the number of
miscarriages associated with invasive testing. “I feel for
women who perhaps have issues and really want to find
out but don’t want to run the risk of a miscarriage”
(D1$). Reducing stress, worry, and offering reassurance
was another common non-monetary outcome of NIPT.
“I think it should be paid for the moment the obstetrician
hands over the pamphlet to a pregnant woman and says
there is a chance that your fetus could have this. Because, it is at that moment that incredible stress is being
put upon a pregnant woman and it’s not good for anyone.
It’s not good for the family unit.” (A2).
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Within these conversations, women often identified
how funding NIPT is related to, or in tension with,
what they identified to be Canadian societal values
about universal health care. Some saw public funding
of NIPT only for women at high risk of aneuploidy
as in conflict with our national commitment to universal care: “I think in our Canadian liberal equal opportunity system if it’s going to be covered it should be
covered [for everyone].” (AP) Others recognized that a
publicly funded healthcare system is always required
to make tough decisions to allocate resources, and
that stratifying access by risk is a reasonable way to
do this: “If you look at our healthcare system, you
want it to be appropriate and you want it based on
needs and not on desire.” (D1$) When describing the
current arrangement of NIPT, many women recognized that the existing implementation of the technology might be described as a “two tier” system, where
inequity of access exists based on ability to pay: “If
you can pay, then you pay. But then that’s a twotiered medical system and nobody likes that.” (A2$)
Many participants recognized the inequity created by
the need to pay privately system, and the difficulty
faced by women who would struggle to pay the cost
of NIPT: “just because we could find $800 doesn’t
mean that we deserve to know that our baby was
okay more than anyone else does.” (A2).
Potential for expansion of NIPT

Our results so far have focused on the ways that NIPT is
currently used and understood by women. However, our
discussions often branched into more speculative waters
as women talked about future potential uses or consequences of NIPT. In these conversations we identified a
tension between women’s desire for reproductive autonomy—to gain information about their pregnancies and
make decisions about their pregnancy based on that information, their values, and personal circumstances—
and a sense of unease or discomfort with how other
women might do the same. While many of our participants wished for some sort of regulation about the potential uses of NIPT, they were uncomfortable with
defining boundaries or specifics of what this regulation
would entail.
Almost all participants were able to identify a scenario
where NIPT could be used for something they felt
should be restricted or prohibited through regulatory
means. Participants had widely varying thresholds for
restricting the use of NIPT. Some common suggestions
for prohibited uses of NIPT included sex selection,
termination on the basis of conditions that had limited,
localized impairments (e.g. deafness or blindness),
termination on the basis of adult-onset conditions (e.g.
Huntington’s disease), termination on the basis of
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physical traits that do not impair functioning (e.g. attached ear lobes). Many women made the distinction
that their objection was not to obtaining knowledge
from NIPT, but to the idea that someone might use that
knowledge to terminate their pregnancy:
“The deaf and blind communities would argue that
they are not disabilities they are just their way of life.
… if someone said to me, we can tell you whether the
baby is going to be deaf or not, do you want to know? I
would probably say yeah I want to know. [but I
wouldn’t choose to terminate for that] … Maybe
someone else would terminate, maybe, that is their
choice. I don’t think people should be allowed to tell
other people how to procreate, or reproduce” (AP)
Others felt that “frivolous” applications should not be
offered in testing at all, regardless of who is paying or
what is done with the information:
“To be honest, I think that my answer is the same
whether we’re paying or the government is paying. I
think that it’s helpful to know anything that can affect
the birth of a healthy child or a childhood disease they
can develop like cystic fibrosis and such but ... I think
it’s crossing over to a whole new realm when you start
talking about finding ... whether they’re going to have
whatever colour hair or things that are not exactly
relevant for when the baby is still in the womb as the
baby and the child. I don’t know, I think that there
should be some limits.” (A2$)
On the other hand, most women also expressed a strong
belief in bodily autonomy and control, access to information about her pregnancy, and the choice to do what
she wanted with that information: “I will make that decision. This is my baby not your baby so if there are options out there, I should know about them. If there’s
additional tests out there that are available, I should
know about them” (A2$). The question of what NIPT
should be used to test for, and who should decide or
control this process aroused discussions of choice, value
systems, autonomy, and the cumulative impact of individual decisions on the diversity of society. “I don’t like
the government making choices for me, but who am I to
say where they stop” (D2$).
Through the discussions of several women we were
able to identify a discomfort with the idea of one policy
or regulation that would apply to all women, or all circumstances: “It’s tough because we’re dealing with such a
broad population of people with very different moral
standards and ethical codes.” (D1) From most of our
participants we heard an acceptance of ambiguity, and a
reluctance to enforce rules or regulations about
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reproduction, even as they recognized the necessity of
these policies. “I don’t know how you make that call, I
don’t know the answer to that. … That’s such a personal
thing and I would never want to make that decision for
somebody else, but you have to have policies that affect
everybody, too, so I don’t know.” (D2$).

Discussion
In this paper, we describe some of the ethical concerns
of women who have personal experience with NIPT,
contributing patient perspectives and experiences to policy considerations of this new technology. Our participants highlighted a variety of ethics issues, many of
which are related to access and self-determination; they
were clear in their message that each woman should be
able to choose when and how she will engage with NIPT,
and how she will use that information. The women in
our study strongly supported public funding for some,
but not all applications of NIPT. They were comfortable
with the general idea of governmental regulation of this
technology, but were reticent to suggest particular limits
on how NIPT should be used. There was little consensus
on the limits that women did suggest, marking an important area for future research and patient engagement.
Within the priorities expressed by our participants, we
note both agreement with and divergence from some of
the normative theoretical positions identified in the
existing ethics literature, and we identify these agreements and disagreements throughout this section.
Ethical issues related to inconsistent implementation of
NIPT

Participants identified several ethical issues resulting
from the way NIPT has been implemented, both the adhoc industry-driven implementation and the 2014 Ontario policy requiring a case-by-case demonstration of
risk to access publicly funded NIPT. We identified a
theme across these issues pertaining to the facilitation or
restriction of women’s autonomous choices about how
they wish to engage with NIPT. Some implementation
issues related to a perception of potentially undue pressure to test, such as the concerns a small number of
women mentioned about industry influence on advertising and informational materials, incentivized health care
professionals, and competition between brands. These
concerns are consistent with ethics issues identified in
the theoretical literature [16, 60, 61], although they were
only mentioned by a small number of very educated
women in our sample. The dominant view across our
participants was a concern that the way NIPT has been
implemented restricts the ability of individual women to
make an autonomous choice about how they wish to
engage with NIPT. This includes disappointment with
incomplete and inconsistent information provided by
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health care professionals, but it mainly pertains to the
lack of a universal offer of NIPT as early as possible in
pregnancy. The expansion of the offer of NIPT, regardless of risk status or funding structure, was a primary
priority of our participants.
This priority remained even when we probed around
ethical arguments against expanding the offer (e.g. inequity of access, potential for iatrogenic anxiety etc.).
While they recognized and affirmed the challenges we
probed with, the vast majority were more concerned
when they found out that NIPT was available but it
hadn’t been offered to them earlier. This finding may reflect both our sampling strategy and the way NIPT has
diffused in Ontario; many of our participants only
learned of the existence of this test after receiving a
positive screen on an earlier test. We have previously
reported patients’ dismay at the use of NIPT in this prenatal care pathway [24].
Our participants’ enthusiasm for an expanded offer of
NIPT contrasts with existing ethics literature detailing
the numerous reasons why an expanded offer may not
be prudent. One caution widely present in the literature
is that an expanded offer of NIPT to all women challenges the ideal of informed decision-making because of
persistent misunderstandings of accuracy, a lack of time
for counselling, sparse availability of counselling specialists, and the potential that the procedurally-simple test
could be easily routinized [15, 41, 42, 48, 51, 62–65].
Additional arguments in the literature against expanding
the offer of NIPT to all women include: the evidence
base in normal-risk women was established only recently, the private-pay nature of the test may discriminate in access, quality assurance measures are not widely
in place, and primary prenatal care providers may not
have the time or expertise available to offer NIPT more
widely [15, 41, 42, 48, 62–64]. Most of these arguments
can be summarized as “we’re not yet ready” rather than
“we shouldn’t”. The strong desire of our participants to
choose whether or not they wish to access NIPT lends
urgency to resolving the challenges around expanding
the offer of this test. This stance is supported by recent
professional guidelines, such as the recommendation
from the American College of Medical Genetics and
Genomics that information about NIPT be provided to
all pregnant women, and that various healthcare stakeholders work to ensure this technology is “accessible” to
all women [66].
Early availability of results

Women recognized both positive and negative implications of the early availability of NIPT results in pregnancy. Positively, they described how receiving NIPT
results early could facilitate self-determination by providing more time to deliberate about the course of the
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pregnancy in the event of a finding of aneuploidy or
other condition. If a woman chooses to terminate the
pregnancy, our participants described several reasons
why this choice is easier earlier in pregnancy. The possibility of early termination has been recognized by
women in many studies as desirable because it is socially, emotionally, physically and psychologically easier,
widening rather than restricting the choices a woman
feels able to consider [63, 67–69].
Our participants identified many potentially negative
aspects to early results which enable easier pregnancy
termination. Primarily, our participants were concerned
that other women may use the information from NIPT
to terminate for “what some of us consider irresponsible
reasons”. Many women talked about sex selection as an
unethical application of NIPT. As our conversations
broadened to the potential expansion of the conditions
tested for by NIPT, the concern that women may use
NIPT to terminate for reasons the participant deemed
“frivolous” deepened. This tension between a desire for
self-determination and a compulsion to regulate the selfdetermination of others is further discussed in the
section on the potential for expanding the conditions offered by NIPT.
Financial considerations

When discussing ethical issues related to finances, cost,
and access, many women in our study leaned heavily on
what they described as Canadian values for publiclyfunded healthcare. We heard familiar rhetoric of scarce
health care resources and the need to allocate those resources in a fair and equitable way that serves the common interest of society rather than the desires of
individuals. Many women offered arguments related to
resource allocation as the only justification for restricting the offer of NIPT, describing that the money spent
on offering NIPT to all women may be better used elsewhere in the healthcare system, such as for the support
of people with disabilities and their families. Others discussed the existing inequity of a “two-tiered” health care
system where people with private means had access to
NIPT which opened earlier access to other related technologies (e.g. invasive testing, termination). For these
women, fairness and equity were important justifications
for funding NIPT for all women.
A concern with equity of access and the potential implications of increasing public investment in a universal
prenatal screening program for disability is an issue
which has been raised by women in a small number of
other studies [68, 70]. For example, van Schendel and
colleagues describe how parents of children with Down
syndrome neatly delineated the tension in this argument
[68]. If NIPT is not publicly funded and only accessed
by those with financial means, “double stigmatization”
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may occur when children with Down syndrome are
more frequently born to those of lower socioeconomic
status. If NIPT is publicly funded, this may increase perceived legitimacy and pressure to test, thereby increasing
uptake and diverting resources (social and financial)
away from the support of people with disabilities and
their families [68]. The concern that increased use of
NIPT will mean decreased support and possibilities for
people living with disability has been well documented
as a concern of women [49, 53, 68, 69, 71, 72] and ethics
scholars [17, 26].
In terms of the transferability of these findings to
other national contexts, most public health care systems
are required to make decisions about how to allocate
scarce resources in terms of the services and tests that
they offer. As more genetic tests become available, the
challenge of fairly allocating scarce public resources becomes an acute problem, requiring ethical reflection
[73]. The views described by women in this study are
relevant to the ethical challenge of priority-setting within
a health system. Our participants recognized that a universal offer of NIPT would be very costly, drawing resources away from other parts of the system. For many,
this was an acceptable reason to forego access to a technology they strongly desired, or to use personal resources to pay for that technology. It was also an
acceptable justification for limiting access to NIPT by
risk status, as a way of triaging resource use.
Potential for expanding the conditions offered by NIPT

Throughout several categories of our findings, we
noticed a tension between women’s desire for the opportunity to use NIPT the way they want (self-determination) and a desire for regulation which would restrict
uses of NIPT they judged to be undesirable (e.g. sex selection). This tension between self-determination and
regulation was particularly acute when we discussed future uses of NIPT, such as the use of NIPT to terminate
for conditions not widely clinically available, but scientifically possible (e.g. achondroplasia, deafness) [74, 75].
This tension in our data highlights one of the challenges
of using the argument of reproductive autonomy to justify prenatal screening. Promoting women’s ability to
make informed decisions about which pregnancies to
continue (reproductive autonomy) is often used to justify
support for prenatal screening even though it may result
in harm to people with disabilities and the diversity of
our society. For those who hold this view, it is difficult
to restrict women’s informed decision-making by delineating types of information they may or may not use to
make that decision [14].
As we probed this issue with participants, many discussed the funding source for NIPT as a way of mitigating the tension between expanding and restricting the
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use of NIPT. Women suggested that perhaps the public
health care system shouldn’t restrict certain applications
of NIPT (e.g. testing in absence of identified risk, testing
for conditions the participant believed to be frivolous),
but neither should the public system financially support
these applications. The willingness of some of our participants to allow a “free market” approach to NIPT is in
stark contrast with ethical writing on the topic, where
ethicists worry about the “trivialization of abortion” that
may arise when NIPT is used to screen and terminate
for non-medical traits under the justification of reproductive choice [76–78]. The view of many of our participants represents a “pure autonomy” or “pure choice”
model, wherein reproductive autonomy and informed
choice is used to justify any prenatal screening decision
a woman wishes to make. The “pure choice” model has
been critiqued by a number of ethicists [79, 80], but a
preference for letting women and their partners choose
what to test for has been expressed by participants in
other empirical studies [47, 68, 69].
These findings suggest that the expansion of NIPT to
conditions beyond those included in traditional prenatal
screening tests is an area which requires urgent ethical
and policy attention. Our participants had strong, but
highly variable opinions on this issue which were often
at odds with ethical scholarship on the topic. Similar
studies of women’s views on the expansion of NIPT have
also demonstrated a high degree of variability of opinion
[68, 69]. Incorporating patient or citizen perspectives
into health policy decision-making is increasingly encouraged in many national and policy contexts, but
there is little guidance available on how to reconcile
conflicts between the views and priorities of patients and
other sources of information (e.g. professional practice
guidelines, ethicists, economists, epidemiologists). It
may be tempting to dismiss patient perspectives when
these conflicts arise. For instance, we may point out that
the women in our study are representative only of themselves, and do not include many important voices or perspectives which may affirm other forms of evidence, or
offer another alternative. Or we may emphasize that the
women in our study are speaking about their personal
experience and values, and when presented with more
information, these views may change. However, to dismiss the views of patients because they are not fully informed or because they represent only themselves
demeans the principle of inclusion of patient and citizen
perspectives. It is important to include these perspectives because they bring an alternative form of information: lived personal experience. To those grappling with
discrepancies or conflicts between patient and expert
views on health policy topics, we suggest that deliberative patient engagement approaches may be a step towards clarification of the values which inform the issue.
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Deliberative patient engagement approaches to research
with women and citizens may help to 1) elicit nuance in
these views; 2) help each side of the issue understand
the issues raised by the other side, potentially identifying
issues of congruence and 3) identify social values which
may assist policy-makers to construct ethical and socially acceptable policy that will keep pace with scientific
advances in this area [37, 81, 82]. Disagreements or discrepancies such as those we highlight here may never be
agreed upon, but deliberative patient engagement
approaches may be one approach to clarifying the
underlying social and ethical values which guide perspectives in diverging directions, offering the opportunity for principled disagreement when one option must
be prioritized over another.

Limitations

Our ethics analysis represents the thoughts, opinions,
and beliefs of women with personal experience of NIPT,
as elicited through qualitative interviews. These women
were older, more educated, and more likely to live in an
urban area than the average Canadian pregnant woman.
Their views are shaped by their individual demographics
and experiences and by their socio-historical location,
and are not intended to be representative of any particular population. The ethical issues identified by women
with personal experience with NIPT may shift, particularly as the scientific, policy, and industry landscape that
shapes the delivery of NIPT changes. As with many
qualitative research studies which rely on volunteer participants, those who were willing to give their time to
discuss their experiences may have a particular interest
in the topic, or in research, which motivated their participation. We succeeded in including participants with a
wide array of experiences of NIPT, but our group is
homogeneous in other ways and so our analysis should
not be considered to represent an exhaustive list of potential ethics implications of NIPT. Indeed, several issues
mentioned in the literature (e.g. genetic privacy of other
relations) were not mentioned by participants. This
study is not patient engagement, but a research study
which solicits perspectives of individuals with relevant
experience of a technology. Since our participants all
had personal experience with the technology, we did not
provide formal education or facilitate a guided deliberation about the technology, as is common in other
methods of patient engagement. Instead, we used a
guided interview strategy to elicit thoughts and opinions
on particular areas of theoretical interest, informed by
the literature and earlier data collection. Data was analyzed through the interpretive lens of the researchers
and the findings are provided for consideration by
policy-makers, clinicians, and users of NIPT.
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Conclusion
This analysis surfaces ethics issues related to noninvasive prenatal screening for the purpose of policy
decision-making. A wide variety of ethics issues are illuminated by talking to people with personal experiences
of the health technology under study—issues that are
often distinct from the issues discussed in the theoretical
literature. The women in our study discussed an extensive variety of ethics implications of NIPT including
some of the ethical challenges that have plagued prenatal
testing for decades (e.g. facilitating informed decisionmaking, judgments about disability) and some new ethical issues specific to NIPT (e.g. expansion of funding
and conditions, implications of early availability of information about fetal sex). However, this technique is not
sufficient to elicit an exhaustive list of potential ethical
issues, nor does it provide definitive normative guidance
for policy decision-making. However, considering the issues identified by women as important to their experience of NIPT is a key aspect of policy-making about
new technology, and when interpreted and considered
through a normative lens of societal values and ethics
priorities contributes to health policy development in
this area.
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